AED | Audio Epilepsy Digest

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making. If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.Episode 4: Drug-Resistant Epilepsy in 2026Does the pathway after two failed antiseizure medications still end in surgery?This episode of Audio Epilepsy Digest looks at the 2026 drug-resistant epilepsy treatment pathway through cenobamate surgery-timing data, the FRANCE anterior thalamic DBS trial, and emerging intracranial biomarker work.The practical message is coexistence, not replacement. Cenobamate may change timing for selected patients, surgical evaluation still matters when a structural target is plausible, ANT-DBS remains palliative rather than curative, and biomarkers are promising research tools rather than current pathway arbiters.Listen and follow Audio Epilepsy Digest:https://audioepilepsydigest.com/AI editorial/source review for this episode:https://audioepilepsydigest.com/episode-004-ai-review.htmlKey takeaways:- Pellinen's cenobamate findings are a single-center association in a selected subgroup, not proof that medication replaces surgery.- Kerr and McFarlane frame the key distinction: surgical delay is not the same as surgical obviation.- FRANCE suggests potential benefit for ANT-DBS in a highly refractory VNS-failed cohort, but it did not prove superiority over best medical therapy.- Aiello's ANT spectral biomarkers are hypothesis-generating and require prospective validation before clinical programming use.Papers discussed:1. Pellinen J, et al. "Delayed and deferred surgery associated with cenobamate use in people with drug-resistant focal epilepsy." Epilepsia (2026). PMID: 41885758.2. Kerr WT, McFarlane KN. "Redefining the treatment pathway for medication-resistant epilepsy in the cenobamate era: Surgical obviation or surgical delay." Epilepsia (2026). PMID: 41972812.3. Chabardes S, et al. "Deep brain stimulation of the thalamus for intractable epilepsy (FRANCE study): A randomized clinical trial." Epilepsia (2026). PMID: 41902639.4. Aiello G, et al. "Intracranial biomarkers for anterior thalamic deep brain stimulation in epilepsy: a long-term observational study." Brain (2026). PMID: 41934257.Source review note:This episode went through AED's automatic two-reviewer source review and regeneration loop. Earlier drafts were rejected or revised before this version cleared with minor caveats.Caveats:- Disparity mechanisms discussed around surgical timing should be understood as hypotheses, not findings directly tested by Pellinen.- Quality of life in FRANCE is multifactorial; palliative seizure-burden reduction should not be treated as equivalent to seizure freedom.- Cenobamate claims should remain anchored to Pellinen's selected subgroup and single-center retrospective design.

> **NOTE:** This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making.> If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.## Episode SummaryWhat should epilepsy care measure when seizure counts are not enough?This episode of *Audio Epilepsy Digest* looks at four recent epilepsy papers that widen the frame beyond seizure frequency. The studies move across respiratory physiology, at-home EEG monitoring, patient-facing seizure terminology, and the lived burden of epilepsy for patients and caregivers.The common thread is measurement humility. Seizure counts remain essential, but they do not capture the whole clinical problem. Better epilepsy measurement will need to integrate physiology, cognition and consciousness, real-world monitoring, patient-reported burden, and caregiver effects while staying honest about what is still research-grade rather than practice-changing.## Key Takeaways- Respiratory physiology may become an important risk-signal domain, but the current respiratory-variability study should not be heard as a validated individual SUDEP prediction tool.- At-home EEG self-monitoring appears feasible for selected, supported patients, but it does not replace routine EEG, ambulatory EEG, EMU evaluation, or expert interpretation.- Patient-facing definitions of ictal impairment of consciousness can be understandable, but terminology comprehension is not the same as proof of improved clinical outcomes.- Patient-burden research reinforces that seizure counts miss mood symptoms, fatigue, sleep disruption, productivity effects, and caregiver burden, while the current survey remains selected and descriptive.## Papers Discussed1. Caplan R, et al. “Association of Interictal Respiratory Variability and Severity of Postictal Hypoxemia After Generalized Convulsive Seizures.” *Neurology* (2026). PMID: 41805401. PMCID: PMC13034677.2. Cousyn L, et al. “Out of the lab, into real life: Evaluating at-home EEG self-monitoring.” *Epilepsia Open* (2026). PMID: 41701004. PMCID: PMC13052238.3. Marcinski Nascimento D, et al. “Persons with epilepsy and their caregivers understand the definition of ictal impairment of consciousness.” *Epilepsia* (2026). PMID: 41705916. PMCID: PMC13075620.4. Wagner S, et al. “What does it mean to live with epilepsy? Burden of illness from the patient perspective.” *Epilepsia Open* (2026). PMID: 41770623. PMCID: PMC13052003.## Source ReviewThis episode went through AED’s transcript-first AI-assisted source review process. The generated audio was transcribed, checked against the full-text source packet, and forced through a pass/revise/regenerate gate. Two earlier audio candidates were rejected before this version cleared AI source review with minor caveats and then passed human audio QA.Read the AI-review note: https://erafat.github.io/audio-epilepsy-digest/episode-003-ai-review.htmlListen and follow:https://erafat.github.io/audio-epilepsy-digest/AI editorial/## Caveats- The respiratory paper supports association and biomarker potential, not individual-level SUDEP prediction.- The home EEG paper supports feasibility in selected, supported patients. Interictal epileptiform discharge concordance with prior in-hospital recordings was reported for three of the four IED-positive participants, but this should not be generalized into replacement of standard clinical EEG workflows.- The terminology paper supports comprehension of a proposed definition, not downstream outcome improvement.- The burden-of-illness paper is descriptive and selected. PHQ-9 and GAD-7 findings are screening results, not formal diagnoses, and the survey does not establish treatment status, mechanism, or medication causality.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making.If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.## DescriptionWhat changes in epilepsy care when we widen the lens beyond raw seizure counts?This episode of Audio Epilepsy Digest looks at four blind spots that appear when epilepsy care is organized too narrowly around seizure counts: etiologic workup after pediatric status epilepticus, early cognitive burden in newly diagnosed focal epilepsy, drug-specific dose logic in idiopathic generalized epilepsy, and the outcome measures used to judge rescue therapy in seizure clusters.The through-line is simple: the right clinical question changes with the problem in front of us. Sometimes the missed issue is genetics. Sometimes it is four-week verbal retention rather than 30-minute recall. Sometimes it is whether escalating lamotrigine is still doing useful work. And sometimes it is whether a rescue medication should be judged by chronic seizure freedom or by the interval between treated clusters.Topics covered:- when pediatric status epilepticus should prompt a stronger genetics-first lens- what the accelerated long-term forgetting paper actually shows, and what it does not, about early memory burden- why ASM dose-response should remain drug-specific rather than assumed to be uniform- why the diazepam nasal spray SEIVAL paper matters more for endpoint design and counseling than for immediate prescribing## Key Takeaways- Pediatric status epilepticus should trigger earlier and more systematic thinking about genetic evaluation, especially in younger children and mixed focal-generalized phenotypes.- The accelerated long-term forgetting signal in newly diagnosed focal epilepsy is task-specific: story memory and verbal recognition look more vulnerable than a blanket all-domain memory model would suggest.- Dose escalation in generalized epilepsy should remain drug-specific rather than assumed to be monotonic across all ASMs, with the strongest practical caution in this cohort applying to lamotrigine doses above the moderate range.- Rescue-medication effectiveness may be better captured by seizure-interval change than by endpoints borrowed from chronic maintenance treatment, but the current SEIVAL paper is best heard as endpoint-development work rather than practice-changing efficacy proof.## Sources1. Marini C, Rosati A, Fusco L, et al. *Neurology* (2026). PMID: 41915870.2. Jackson CF, Makin SM, Mohanraj R, et al. *Epilepsy & Behavior* (2026). PMID: 41707288.3. Abdullah-Roskjær A, Gesche J, Rubboli G, Beier CP. *Epilepsy & Behavior* (2026). PMID: 41707289.4. Kerr WT, McFarlane KN, Ngo LY, et al. *Epilepsia* (2026). PMID: 41919765.## Caveats- The selected papers pull in different practice domains, so the episode is a synthesis rather than a single tightly focused controversy packet.- Some conclusions remain provisional and should be heard in light of study design limitations and generalizability constraints.- The diazepam paper is a post hoc open-label reanalysis with industry funding, an internal baseline, and unmeasured longitudinal confounding.- The IGE dosing paper is retrospective, uses self-reported seizure outcomes, and does not model combination therapy or serum levels cleanly.- The ALF paper is small and task-specific, so its main value is sharpening how we talk about early cognitive burden rather than defining a broad screening protocol.

NOTE: This podcast is an evolving collaboration between human and AI. While we strive for accuracy, AI hosts may misinterpret or oversimplify source material. Always refer to the original published articles for clinical decision-making.If you find any claims made by the AI hosts to be inaccurate, please let us know. Your feedback directly improves future episodes.Should thalamic sEEG sampling be standard of care, selectively hypothesis-driven, or research-only?This first Audio Epilepsy Digest release takes up the February 2026 Brain debate cluster on thalamic stereoEEG and focuses on what actually matters for epileptologists at academic centers: SEEG planning, neuromodulation targeting, safety, ethics, and institutional policy.In this episode, the hosts examine:- whether thalamic sampling changes real clinical decision-making- when thalamic signals may be justified in hypothesis-driven intracranial exploration- how the argument shifts when neuromodulation planning is part of the goal- where the current literature reflects expert interpretation more than settled comparative outcomes evidenceThis is a source-grounded special episode built from a tightly related editorial-plus-opinions packet, so the goal is not to force false consensus. The takeaway is a practical policy conversation for current practice, with explicit attention to what remains uncertain.--## SummaryThis special episode of *Audio Epilepsy Digest (AED)* takes up a narrow but consequential controversy from the February 2026 *Brain* thalamic stereoEEG cluster: should thalamic sampling be routine clinical practice, a selectively justified extension of hypothesis-driven exploration, or remain largely research-only?The discussion focuses on what the debate actually means for SEEG planning, neuromodulation strategy, safety, ethics, and institutional policy in academic epilepsy centers.## Key Takeaways- The strongest argument for restraint is not that thalamic recordings are never interesting, but that incremental patient-level clinical benefit remains uncertain in many cases and may not justify routine added sampling.- The strongest argument for selective clinical use is that thalamic signals can become decision-relevant when the pre-implant hypothesis already involves network propagation, neuromodulation targeting, or uncertainty that cortical-only sampling may not resolve.- The pro-neuromodulation position is more intervention-oriented than the stricter research-only framing and treats thalamic sampling as part of a therapeutic planning workflow, not only a localization experiment.- Much of the packet is interpretation and expert argument rather than direct comparative outcomes evidence, so this should be heard as a policy and practice debate, not a settled consensus statement.## Sources1. *Brain* 149(2):361. "Should thalamic recording be standard practice or institutional review board-approved research in stereoEEG?"2. *Brain* 149(2):371. "Thalamic stereoEEG evaluation: is it justified in clinical practice?"3. *Brain* 149(2):373. "Thalamic stereo EEG: a clinically justified extension of hypothesis-driven intracranial exploration."4. *Brain* 149(2):375. "Thalamic stereoEEG optimizes neurostimulation therapy."5. *Brain* 149(2):378. "The role of thalamic stereoEEG in epilepsy clinical practice."## Caveats- This is mainly a debate packet built from editorial and opinion writing rather than randomized trials or head-to-head outcomes studies.- The packet is strong on coherence, but much of the force of the discussion comes from author framing and interpretation.- The local full-text set came from browser extracts because Oxford PDF endpoints remained blocked under automation.